Frontiers in Medicine (Apr 2022)

Combination of Fat-Free Muscle Index and Total Spontaneous Portosystemic Shunt Area Identifies High-Risk Cirrhosis Patients

  • Anton Faron,
  • Jasmin Abu-Omar,
  • Johannes Chang,
  • Nina Böhling,
  • Alois Martin Sprinkart,
  • Ulrike Attenberger,
  • Jürgen K. Rockstroh,
  • Andreas Minh Luu,
  • Christian Jansen,
  • Christian P. Strassburg,
  • Jonel Trebicka,
  • Jonel Trebicka,
  • Julian Luetkens,
  • Michael Praktiknjo

DOI
https://doi.org/10.3389/fmed.2022.831005
Journal volume & issue
Vol. 9

Abstract

Read online

BackgroundSarcopenia and spontaneous portosystemic shunts (SPSSs) are common complications of liver cirrhosis, and both are associated with higher rates of hepatic encephalopathy (HE) development in these patients. This study aimed to evaluate the simultaneous impact of skeletal muscle mass and spontaneous portosystemic shunting, measured from routine diagnostic CT on outcomes in patients with liver cirrhosis.MethodsRetrospective analysis of patients with cirrhosis. Skeletal muscle mass [including fat-free muscle index (FFMI) as a surrogate for sarcopenia] and total cross-sectional spontaneous portosystemic shunt area (TSA) were quantified from CT scans. The primary endpoint was the development of HE, while the secondary endpoint was 1-year mortality.ResultsOne hundred fifty-six patients with liver cirrhosis were included. Patients with low (L-) FFMI and large (L-)TSA showed higher rates of HE development. In multivariable analysis, L-FFMI and L-TSA were independent predictors of HE development (L-FFMI HR = 2.69, CI 1.22–5.93; L-TSA, HR = 2.50, CI = 1.24–4.72) and 1-year mortality (L-FFMI, HR = 7.68, CI 1.75–33.74; L-TSA, HR = 3.05, CI 1.32–7.04). The simultaneous presence of L-FFMI and L-TSA exponentially increased the risk of HE development (HR 12.79, CI 2.93–55.86) and 1-year mortality (HR 13.66, CI 1.75–106.50). An easy sequential algorithm including FFMI and TSA identified patients with good, intermediate, and poor prognoses.ConclusionThis study indicates synergy between low skeletal muscle mass and large TSA to predict exponentially increased risk of HE development and mortality in liver cirrhosis. Simultaneous screening for sarcopenia and TSA from routine diagnostic CT may help to improve the identification of high-risk patients using an easy-to-apply algorithm.Clinical Trial registration[ClinicalTrials.gov], identifier [NCT03584204].

Keywords